[Dynamics of immunoglobulin production in non infected children born from HIV-1 infected mothers: effect of zidovudine].
BACKGROUND
To evaluate the possible effect of zidovudine (ZDV) on inmunoglobins production in infants born to HIV-1 infected women.


METHODS
We have studied the immunoglobulins serum levels in 57 non-infected children born to HIV-infected mothers. The children were divided into two groups: group A, 28 children born to HIV-1 infected mothers that received ZDV on protocol 076 conditions, and group B, 29 children born to mothers that did not receive anti-HIV-1 drugs. Quantification of serum IgG, IgA and IgM was performed by nephelometric techniques.


RESULTS
The median time to reach normal IgA values at 12 months, was 25.57 months (confidence interval [CI] 95%: 22.01-29.12) in the children of group A and 12.67 months (CI 95%: 9.90-15.44) in the children of group B (p = 0.01). The median time to reach normal IgM values at 12 months was 15.93 months (CI 95%: 15.21-16.65) in group A children versus 11.20 months (CI 95%: 8.51-13.89) in group B (p = 0.11). The median time to reach normal IgG values at 12 months was 19.67 months (CI 95%: 13.12-16.22) in group A children versus 12.73 months (CI 95%: 11.16-14.30) in group B (p = 0.05). The normal IgA levels were reached 2.36 (CI 95%: 1.16-4.81) times later in group A than in group B children (p = 0.02), whereas normal IgG levels were reached 1.88 (CI 95%: 0.94-3.78) times later in group A than in group B of children.


CONCLUSIONS
Our results indicate that treatment of pregnant mothers with ZDV clearly affect the ability of their newborns to produce inmunoglobulins, which may have important practical implications for their vaccination protocols.
Resino
S
S
División de Inmunología, Hospital General Universitario Gregorio Marañón, Madrid.
Gurbindo
M D
MD
Bellón
J M
JM
Jiménez
J L
JL
León
J A
JA
Navarro
J
J
Muñoz-Fernández
M A
MA
D019380:Anti-HIV Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D000917:Antibody Formation / Q000187:drug effects / Q000276:immunology; D005260:Female; D006679:HIV Seropositivity / Q000188:drug therapy* / Q000276:immunology*; D006801:Humans; D007136:Immunoglobulins / Q000096:biosynthesis / Q000187:drug effects / Q000276:immunology; D007223:Infant; D007229:Infant Welfare; D007231:Infant, Newborn; D008429:Maternal Welfare; D011247:Pregnancy; D012189:Retrospective Studies; D015215:Zidovudine / Q000494:pharmacology* / Q000627:therapeutic use*
D019380:Anti-HIV Agents; D007136:Immunoglobulins; D015215:Zidovudine
Dinámica de producción de inmunoglobulinas en niños no infectados nacidos de madres infectadas por el VIH-1: efecto de la zidovudina.